Putting the Guidelines into Practice: Building a State-of-the-Art Lipid and Cardiometabolic Clinic-Cardiovascular-Kidney-Metabolic Syndrome: A Comprehensive Framework for Risk Assessment and Treatment

Cardiovascular-Kidney-Metabolic Syndrome: A Comprehensive Framework for Risk Assessment and Treatment

Video Transcription

Video Summary

CKM syndrome describes interconnected heart disease, kidney disease, diabetes, and obesity that share pathophysiology (dysfunctional adiposity, inflammation, insulin resistance) and drive rising, synergistic premature cardiovascular mortality. A four-step care framework is proposed: (1) Screen with cardiovascular health metrics plus labs (lipids, glycemia, eGFR) and emphasize urine albumin–creatinine ratio; also screen for fatty liver disease (FIB-4). (2) Assess quantitative risk using the AHA PREVENT calculator, incorporating social deprivation. (3) Determine CKM stage (0–4) reflecting progression to subclinical and then clinical CVD. (4) Reduce risk via obesity treatment, cardioprotective glucose therapies (GLP-1/dual agonists, SGLT2 inhibitors), BP, kidney-protective agents, and lipid lowering, delivered through coordinated, team-based care addressing social determinants.

Keywords

CKM syndrome

cardiometabolic-kidney disease framework

AHA PREVENT risk calculator

urine albumin-creatinine ratio screening

GLP-1 and SGLT2 cardioprotective therapy